FcγRIIb blockage:a promising immunotherapy target for severe COVID-19  

作　　者：Xuemei He Manni Wang Min Wu 

机构地区：[1]Laboratory of Aging Research and Cancer Drug Target,State Key Laboratory of Biotherapy and Cancer Center,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu,Sichuan,P.R.China [2]Department of Biomedical Sciences,University of North Dakota School of Medicine and Health Sciences,Grand Forks,ND,USA

出　　处：《Signal Transduction and Targeted Therapy》2021年第5期1396-1398,共3页信号转导与靶向治疗（英文）

摘　　要：A recent study published in Nature by Combes et al.1 introduced a whole-blood-preserving single-cell analysis strategy to explore the contributions of the immune cells,including neutrophils,monocytes,platelets,and lymphocytes.The team comprehensively analyzed a variety of cellular and serological immune features between severe and mild to moderate phenotypes of patients with coronavirus disease 2019(COVID-19),in order to identify potential targets of immunotherapies for the severe COVID-19 patients who need prompt and effective treatments.

关 键 词：al. PATIENTS IMMUNOTHERAPY 

分 类 号：R730.51[医药卫生—肿瘤]